Atopic Dermatitis (Eczema) clinical trials at UCSF
4 in progress, 2 open to new patients

  • A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis

    open to eligible people ages 3 months to 23 months

    This 4-week study will evaluate the safety, pharmacokinetics (PK), and efficacy of crisaborole ointment 2%, applied twice daily (BID) in subjects who are 3 months to less than 24 months of age with mild-to-moderate AD.

    San Francisco, California and other locations

  • Systemic Therapies for Pediatric Atopic Dermatitis

    open to eligible people ages 2-17

    While many patients with atopic dermatitis (eczema) can be managed with topical creams and treatments for itch, some children have such severe, long-standing disease that they need treatment with oral medications that decrease the ability of the immune system to react. However, there is not enough information on the proper use of these medications or how well they work compared with each other. The current study looks at the response of children treated with these medications to provide this information and improve their use.

    San Francisco, California and other locations

  • Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis

    Sorry, not yet accepting patients

    This is a single-arm, open-label study, which will examine the effect of dupilumab on the immunologic and genetic environment within atopic dermatitis lesions.

    San Francisco, California

  • The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients

    Sorry, not yet accepting patients

    This is a single-arm, open-label study, which will examine the effect of dupilumab on quality of life in atopic dermatitis patients.

    San Francisco, California

© The Regents of the University of California